Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2015-05-18 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2014年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2014 Annual General Meeting (AGM) of a company. It details the legality and procedural compliance of the AGM, including the convening, attendance, agenda items, and voting results. The document does not contain the actual annual report or financial statements but rather focuses on the legal aspects of the AGM process. This type of document is typically classified as AGM Information (AGM-R), as it relates to materials shared or produced in connection with the AGM, specifically a legal opinion on the meeting's conduct.
2015-05-18 Chinese
2014年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a detailed announcement of the resolutions passed at the 2014 Annual General Meeting (AGM) of 普洛药业股份有限公司. It includes voting results on various proposals such as the 2014 annual report, board work report, financial report, profit distribution plan, election of directors, appointment of auditors, amendments to the articles of association, and non-public issuance of A shares. The document also mentions the meeting's convening details, attendance, and legal opinions confirming the validity of the meeting and resolutions. The content is focused on the official voting results and decisions made at the AGM rather than the full annual report or other financial statements themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting data, confirming it is not a mere announcement of a report publication (RPA) or a regulatory filing (RNS).
2015-05-18 Chinese
关于召开2014年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2014 Annual General Meeting (AGM) of 普洛药业股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders on how to participate and vote. The document does not contain the actual annual report or financial statements but rather serves as a notice and guide for shareholders about the upcoming AGM and the related voting process. The presence of agenda items such as the 2014 annual report, board reports, profit distribution plan, and proposals for non-public stock issuance indicates it is an AGM notice. Given the document length and content, it is not a brief announcement but a comprehensive AGM notification. Therefore, the appropriate classification is AGM Information (AGM-R).
2015-05-13 Chinese
西南证券股份有限公司关于公司2014年度保荐工作报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2014年度保荐工作报告' which translates to '2014 Annual Sponsorship Work Report' by Southwest Securities Co., Ltd. regarding Puluo Pharmaceutical Co., Ltd. It details the sponsorship work overview, issues found, measures taken, and fulfillment of commitments by the company and shareholders. The content focuses on the sponsor's review and supervision activities, company governance, and compliance with commitments related to a non-public stock issuance. There are no financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). The document is a detailed report on sponsorship work, which aligns with an Audit Report / Information (AR) category as it relates to regulatory and compliance oversight rather than a full annual report or earnings release. The document length is 3438 characters, which is substantive and not a mere announcement or certification. Therefore, the best fit is Audit Report / Information (AR). FY 2014
2015-05-05 Chinese
西南证券股份有限公司关于公司发行股份购买资产并募集配套资金暨关联交易之2014年度持续督导工作报告书
Capital/Financing Update Classification · 95% confidence The document is a detailed report by an independent financial advisor (西南证券股份有限公司) regarding a major asset acquisition and related fundraising by 普洛药业股份有限公司. It includes extensive information on the issuance of shares to purchase assets, the completion of asset transfer and registration, fundraising details, use of funds, and fulfillment of various commitments related to the transaction. The document references regulatory approvals from the China Securities Regulatory Commission (证监会) and Shenzhen Stock Exchange (深交所), and contains financial data, transaction details, and compliance information. The document is titled as a "2014年度持续督导工作报告书" (2014 Annual Continuous Supervision Work Report) related to the issuance of shares for asset purchase and fundraising, which aligns with a report on a capital/financing update and related ongoing supervision of a major asset restructuring. It is not a full annual report (10-K), nor a simple announcement. It is a comprehensive supervisory report on a capital transaction and related compliance, which fits best under Capital/Financing Update (CAP).
2015-05-05 Chinese
西南证券股份有限公司关于公司2015年度预计日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion from Southwest Securities Co., Ltd. regarding the 2015 expected routine related party transactions of Proya Pharmaceutical Co., Ltd. It includes detailed descriptions of related party transactions, pricing principles, approval procedures, independent directors' opinions, and the sponsor's verification opinion. The document is a formal verification and opinion report on expected related party transactions for the upcoming fiscal year, prepared by the sponsor institution. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification but a detailed verification opinion on related party transactions, which aligns with the nature of an Audit Report / Information (AR) category, as it involves applied accounting principles and regulatory compliance related to transactions. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2015
2015-05-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.